Triple therapy shows promise for advanced liver cancer

NCT ID NCT05332821

Completed Disease control Sponsor: Zhongda Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a triple combination treatment for advanced liver cancer that has spread. It combines a procedure called TACE (which blocks blood flow to the tumor) with immunotherapy drugs (PD-1/PD-L1 inhibitors) and targeted therapies (VEGF-TKI or bevacizumab). The goal is to improve overall survival and control cancer progression. Over 1,200 participants with advanced-stage hepatocellular carcinoma were enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PD-1/PD-L1 inhibitors (e.g., atezolizumab, pembrolizumab) and VEGF-TKI/bevacizumab (e.g., sorafenib, lenvatinib)
What this could lead to: If successful, this combination could offer a new standard treatment to extend life and control advanced liver cancer that has spread.
What could go wrong: This is a completed study, but results are not yet published. The combination may cause significant side effects, and not all patients may benefit equally.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Gao-Jun Teng

Nanjing, China
Zheng-Gang Ren

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.